Bluebird Bio (BLUE) Stock Price, Quote & News

Company Profile

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cereb...

Industry: Biotechnology

Sector: Healthcare

Phone: 339 499 9300

Website: www.bluebirdbio.com

Address:

455 Grand Union Boulevard, Somerville, United States

AshHydrogen Aug. 7 at 1:01 AM

$PLTR $SPY $BLUE $SKY BREAKOUT to the $MOON

0 · Reply

AshHydrogen Aug. 7 at 12:58 AM

$PLTR $SPY $BLUE $SKY BREAKOUT TOMORROW!!!

0 · Reply

paarthshah0050 Aug. 6 at 2:47 PM

Stocks to Watch Tomorrow 🧑‍💻🧑‍🏫📊 Longs 📈📈📈 Reliance Bel Eternal Shorts 📉📉📉 Bluestar Shree cem Tcs 📌 Disc - Do Your analysis also before Taking Trades $BLUE

0 · Reply

jrh34 Jul. 17 at 3:13 AM

$CRDF I've been involved in few shit-show, gone sideways, type biotechs ( $BLUE $ITRM to name a few) in all those cases, I've NEVER seen a insider step up and buy shares - a sure sign they were in the death spiral. But here? We've got the CEO and a senior board member buying close to $1 Million in shares. They have to know something the rest of us pee-ons don't.

1 · Reply

Wizardof0z Jul. 16 at 11:17 AM

$BLUE $CXAI $LIMN $VMAR don’t sleep the rocket has blasted LIMN about to reach the moon

0 · Reply

TheOne_24 Jul. 16 at 11:14 AM

$LIMN $CXAI $VMAR $BLUE $LIMN — Don’t sleep on the setup. 👀🔥 Fear creates opportunities, and small-cap biotech is where sentiment can flip fast. LIMN is positioned in the oncology space with a pipeline focused on next-generation cancer therapies, while strategic financing efforts provide a path toward advancing development. The market cap leaves room for significant moves when catalysts hit, and a reclaim of key resistance levels with volume could bring momentum back quickly. 📈 Strong science + biotech upside + low valuation = a setup worth watching. The crowd usually notices after the move starts. 🚀 Do your own research. High risk, high reward. #LIMN #Biotech #CancerResearch #SmallCaps

0 · Reply

Playingforfun Jul. 10 at 10:44 PM

$BLUE https://www.bizjournals.com/boston/news/2026/07/09/meet-new-bluebird-genetix.html

0 · Reply

Playingforfun Jul. 3 at 12:06 PM

$BLUE any word on if they hit any of their benchmarks?

0 · Reply

MF__DOOM Jun. 17 at 12:07 PM

$BLUE $CRSP $QQQ $QURE $SPY 80-100

0 · Reply

Dkll303 Jun. 4 at 9:40 AM

$BLUE $CRSP $QQQ $QURE $SPY And so dumb, BLUE was bought out 2 years ago for 300M ..all done there !

0 · Reply

bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots

Jul 1, 2025, 9:00 AM EDT - 1 year ago

bluebird bio Strengthens Leadership Team With New Appointments

Jun 2, 2025, 8:34 AM EDT - 1 year ago

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

May 30, 2025, 8:30 AM EDT - 1 year ago

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

May 27, 2025, 8:30 AM EDT - 1 year ago

bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital

May 16, 2025, 4:30 PM EDT - 1 year ago

Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions

May 14, 2025, 8:52 AM EDT - 1 year ago

Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital

May 14, 2025, 8:30 AM EDT - 1 year ago

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement

May 9, 2025, 8:30 AM EDT - 1 year ago

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

May 5, 2025, 4:00 PM EDT - 1 year ago

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

Apr 16, 2025, 8:00 AM EDT - 1 year ago

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

Mar 28, 2025, 5:43 PM EDT - 1 year ago

Bluebird bio receives non-binding bid for up to $110.5 million

Mar 28, 2025, 5:06 PM EDT - 1 year ago

Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update

Mar 28, 2025, 4:15 PM EDT - 1 year ago

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

Mar 13, 2025, 3:43 PM EDT - 1 year ago

BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE

Feb 21, 2025, 3:43 PM EST - 1 year ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.

Feb 21, 2025, 1:48 PM EST - 1 year ago

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Feb 21, 2025, 9:45 AM EST - 1 year ago

bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs

Feb 21, 2025, 8:04 AM EST - 1 year ago

Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch

Feb 21, 2025, 7:30 AM EST - 1 year ago

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

Feb 18, 2025, 9:52 AM EST - 1 year ago

High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models

CVS VRTX

Dec 8, 2024, 12:30 PM EST - 1 year ago

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 7, 2024, 12:00 PM EST - 1 year ago

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Dec 4, 2024, 4:05 PM EST - 1 year ago

bluebird bio Announces 1-for-20 Reverse Stock Split

Dec 4, 2024, 8:47 AM EST - 1 year ago

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

Nov 27, 2024, 11:45 AM EST - 1 year ago

FDA investigates risk of blood cancers from bluebird bio's gene therapy

Nov 14, 2024, 7:00 AM EST - 1 year ago

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Nov 6, 2024, 4:15 PM EST - 1 year ago

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

Nov 5, 2024, 9:05 AM EST - 1 year ago

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Oct 8, 2024, 3:53 PM EDT - 1 year ago

Bluebird Bio (BLUE) Stock Dips Amid Market Volatility

Oct 4, 2024, 4:05 PM EDT - 2 years ago

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2024, 4:11 PM EDT - 2 years ago

Bluebird Bio (BLUE) Stock Surges 5.04% Amid Market Movements

Sep 27, 2024, 4:30 PM EDT - 2 years ago

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Sep 24, 2024, 7:08 AM EDT - 2 years ago

Bluebird bio to cut 25% of workforce as part of restructuring

Sep 24, 2024, 7:00 AM EDT - 2 years ago

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

Sep 13, 2024, 4:41 PM EDT - 2 years ago

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

Aug 28, 2024, 8:00 AM EDT - 2 years ago

bluebird bio Announces September Investor Events

Aug 23, 2024, 4:05 PM EDT - 2 years ago

bluebird bio Announces Receipt of Expected Notices from Nasdaq

Aug 14, 2024, 7:00 AM EDT - 2 years ago

bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Aug 12, 2024, 8:00 AM EDT - 2 years ago

bluebird bio Announces Second Quarter 2024 Results Call Date

Aug 2, 2024, 4:05 PM EDT - 2 years ago

bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2024, 4:05 PM EDT - 2 years ago

bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2024, 10:15 PM EDT - 2 years ago

2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

AshHydrogen Aug. 7 at 1:01 AM

$PLTR $SPY $BLUE $SKY BREAKOUT to the $MOON

0 · Reply

AshHydrogen Aug. 7 at 12:58 AM

$PLTR $SPY $BLUE $SKY BREAKOUT TOMORROW!!!

0 · Reply

paarthshah0050 Aug. 6 at 2:47 PM

Stocks to Watch Tomorrow 🧑‍💻🧑‍🏫📊 Longs 📈📈📈 Reliance Bel Eternal Shorts 📉📉📉 Bluestar Shree cem Tcs 📌 Disc - Do Your analysis also before Taking Trades $BLUE

0 · Reply

jrh34 Jul. 17 at 3:13 AM

1 · Reply

Wizardof0z Jul. 16 at 11:17 AM

$BLUE $CXAI $LIMN $VMAR don’t sleep the rocket has blasted LIMN about to reach the moon

0 · Reply

TheOne_24 Jul. 16 at 11:14 AM

0 · Reply

Playingforfun Jul. 10 at 10:44 PM

$BLUE https://www.bizjournals.com/boston/news/2026/07/09/meet-new-bluebird-genetix.html

0 · Reply

Playingforfun Jul. 3 at 12:06 PM

$BLUE any word on if they hit any of their benchmarks?

0 · Reply

MF__DOOM Jun. 17 at 12:07 PM

$BLUE $CRSP $QQQ $QURE $SPY 80-100

0 · Reply

Dkll303 Jun. 4 at 9:40 AM

$BLUE $CRSP $QQQ $QURE $SPY And so dumb, BLUE was bought out 2 years ago for 300M ..all done there !

0 · Reply

Dkll303 Jun. 4 at 9:40 AM

$BLUE $QURE this @MF_DOOM character is a options player ..believe nothing he says …he has been here before touting higher prices and leaves when this hits $30 ..( use to be $25 ) so his rhetoric is garbage…

0 · Reply

MF__DOOM Jun. 3 at 10:07 PM

$QURE go long kid, I was thinking BO around $80-100 but we may not even need a BO for that price point to be obtainable now but I do still think a BO is possible and on the table here in the long term…let’s see as more time passes $BLUE $CRSP $SPY $QQQ

1 · Reply

MF__DOOM Jun. 3 at 10:02 PM

$QURE 👀 $SPY $QQQ Rip $BLUE $CRSP

0 · Reply

JPtheBCRXdestroyer1 May. 23 at 7:34 PM

$BLUE sounds like $BCRX woke grifters scamming the system sending money back to Pakistan to be used to subvert America. Supported by woke terrorists that want to subvert America. Show them what America is made of Wall Street. If this company wasn't all about scamming the system for money it would be working on drugs for important conditions like ARDS which just took American hero Kyle Busch

4 · Reply

dmoney8989 Apr. 17 at 1:44 PM

$BLUE check out $HIMS

0 · Reply

stu4 Apr. 2 at 10:08 AM

$CADL $TNXP $BLUE forgot to add Nick Leschly , CEO of the failed bluebird bio and recently fcuked up $TSVT . He too lied to the street , as TAK has and continues to do, and like NICK, Wall Street will fcuk him over .

1 · Reply

MF__DOOM Mar. 6 at 6:58 PM

$QURE come on baby don’t treat me like $BLUE did I think we get a major bo here in the coming years $80-100 zone $SPY $QQQ $XBI

0 · Reply

MF__DOOM Mar. 2 at 6:41 PM

$QURE bought a bit more at $10 Not a fan but still like it for the end play of a BO starting to be scary though like $BLUE hopefully this isn’t a repeat with the BO process $80-100 those who sold at $70 did dodge a bullet so far though

0 · Reply

Universal6999 Feb. 26 at 1:56 PM

$BGL $BLUE Gold Limited of course should had sold

0 · Reply

Dkll303 Feb. 20 at 1:25 AM

$CADL I’m not waiting ..I knew the scenario Nick Leschly did the same siht !!! At $BLUE

0 · Reply

Market Cap	48.67M
Revenue (ttm)	83.81M
Net Income (ttm)	-240.72M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-287.22%
Debt to Equity Ratio	-2.02

Volume	1,245,100
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	9.79M
Stochastic %K	N/A
Beta	0.27
Analysts	Hold
Price Target	$9.33